Physician profile
Robert Main
NPI 1689614711
$10,573.87
in general payments reported to CMS, 2019-2025
39 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,765 · 2022: $2,009 · 2023: $1,369 · 2024: $2,672 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,785 · Education: $14.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.44 |
| Education | $14.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,815.64 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,694.22 | 2021-2025 | Zeposia |
| Amgen INC. | $1,049.39 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $759.57 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $679.52 | 2021-2023 | |
| Novo Nordisk INC | $485.41 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Harmony Biosciences LLC | $371.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.87 | 2021-2025 | Ofev |
| Lilly USA, LLC | $328.36 | 2021-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $318.16 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $284.96 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $259.50 | 2022-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $217.69 | 2024-2025 | Voquezna |
| Merz North America, INC. | $199.46 | 2021 | |
| Corium, LLC | $191.08 | 2022-2023 | Azstarys |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Main listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.